Olaxinn

Quick links to important sections

Olaxinn

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Olaxinn

Olaxinn is a prescription-only psychotropic medication used to help stabilize severe mental health conditions characterized by disruptions in thought, mood, and perception.

Property Description
Active ingredient Olanzapine (a single-ingredient product)
Form Tablet (oral), Orally Disintegrating Tablet (ODT), Solution for Injection
Pharmacological class Atypical Antipsychotic (Second-Generation Antipsychotic, SGA)
Common purpose Stabilizing mood, thought, and perception
Origin Synthetic Compound (Thienobenzodiazepine derivative)

Olaxinn’s Classification and Core Identity

Olaxinn contains the active component Olanzapine, which is classified as an atypical antipsychotic, also known as a Second-Generation Antipsychotic (SGA). This drug is a purely synthetic compound derived from the thienobenzodiazepine chemical family.

This classification is clinically recognized for its balanced mechanism. The general therapeutic purpose of the medication is to stabilize thought processes and help manage severe fluctuations in mood. It works by adjusting the complex activity of certain natural substances, such as dopamine and serotonin, in the brain, thereby supporting a more regulated state of mind.


Available Forms and Differentiating Features

Olanzapine is available under the name Olaxinn in several dosage forms, including the standard tablet for oral ingestion, a specialized orally disintegrating tablet (ODT), and a sterile solution for injection for the intramuscular route. The availability of the ODT formulation, which dissolves rapidly on the tongue, is a distinctive feature. This design provides practical administrative flexibility, particularly for patients who may experience difficulty swallowing, helping to ensure consistent and reliable drug intake.

What side effects are possible with Olaxinn?

Olaxinn's safety profile, based on official regulatory documents, is structured around frequently observed effects related to metabolism and the central nervous system, alongside warnings for rare but serious adverse reactions.

Adverse Reaction Scope

Category Description based on Regulatory Documents
Key adverse reaction categories Metabolic/Endocrine (e.g., weight gain, dyslipidaemia, hyperglycaemia), Nervous System (e.g., somnolence, dizziness), and Vascular (e.g., orthostatic hypotension).
Frequency classification Officially categorized from Very Common (may affect more than 1 in 10 people, such as weight gain and somnolence) to Rare (may affect up to 1 in 1,000 people, such as seizures or thromboembolic events).
Serious adverse reactions Neuroleptic Malignant Syndrome (NMS), severe hyperglycemia potentially leading to ketoacidosis/coma, Tardive Dyskinesia, and serious Cerebrovascular Adverse Events (CVAE).

Safety Classifications (High-Level)

  • Population-specific safety considerations: Older adults with dementia-related psychosis have an officially documented increased risk of death and CVAE (stroke or transient ischemic attack). Olaxinn is not approved for the treatment of psychosis in this specific patient population.
  • Dose- or exposure-related patterns: Orthostatic hypotension (postural dizziness) and somnolence are frequently observed upon treatment initiation. The risk of significant weight gain and tardive dyskinesia is associated with long-term exposure. Abrupt cessation carries the risk of acute withdrawal symptoms.
  • Safety-related restrictions: Regulatory documents require periodic monitoring of fasting blood glucose and lipid profiles at the start of treatment and throughout its duration due to the documented metabolic risks.

Connection to the Overall Safety Profile

This framework organizes the drug's safety information by frequency and affected body system, emphasizing that metabolic dysfunction and neurological effects are primary regulatory concerns, which necessitates mandated monitoring. The official safety constraints underscore an absolute restriction in its use for the specific patient group of older adults with dementia-related psychosis due to the documented, elevated mortality risk.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented manifestations and required emergency actions for an overdose of Olaxinn (Olanzapine), based on governmental regulatory prescribing information.

Documented Manifestations and Severe Outcomes

Manifestations range from common signs of central nervous system (CNS) depression to severe, life-threatening events.

System Documented Signs and Symptoms
CNS/Neurological Somnolence, slurred speech, agitation, extrapyramidal symptoms, seizures, coma.
Cardiovascular Tachycardia, hypotension, QTc prolongation, cardiac dysrhythmia, ventricular fibrillation, sudden death.
Other Respiratory depression, miosis (pinpoint pupils), hyperpyrexia (high fever).

Required Emergency Actions

Management of an Olaxinn overdose is primarily symptomatic and supportive, as no specific antidote is documented in official labeling. Close medical supervision and continuous cardiovascular monitoring are required until recovery.

Urgent medical attention must be sought immediately if any victim has collapsed, had a seizure, has trouble breathing (respiratory depression), or cannot be awakened (coma). In such cases, the regulatory instruction is to call emergency services immediately.

Management procedures include ensuring an open airway and adequate ventilation. Regulatory documents explicitly advise against using epinephrine, dopamine, or other beta-agonist agents, as this may worsen low blood pressure.

Therapeutic Uses of Olaxinn

What Olaxinn Treats: Main Uses and Benefits

Olaxinn (Olanzapine) is commonly used to help with major psychiatric illnesses. This includes managing conditions such as Schizophrenia and Bipolar I Disorder and is applied in addressing conditions involving episodic or fluctuating manifestations. It is also relevant in situations where patients experience treatment-resistant depression.

Olaxinn is relevant for conditions characterized by periods of heightened symptoms. It plays a role in managing symptom clusters that may become intense or disruptive, such as hallucinations, delusions, racing thoughts, and severe agitation. Applied in clinical settings that involve acute or unstable symptom patterns, it provides support that helps ease the overall symptom load when symptoms become temporarily overwhelming.

“This medication is applied across domains where additional symptomatic support is needed, assisting with maintaining functional stability.”

Quick Fact: Relief for Behavioral Distress

Olaxinn is often used when symptoms intensify and supportive relief is needed to address acute behavioral symptoms like hostility and psychomotor restlessness. This supports patients during episodes of heightened discomfort.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The eligibility for Olaxinn use is strictly defined by regulatory documents based on age, physiological state, and pre-existing conditions.

Populations for Whom Use is Contraindicated

Use is prohibited for any patient with a known hypersensitivity to olanzapine or its excipients. The medicine is contraindicated for older adults with dementia-related psychosis due to a documented increase in mortality risk. Patients with known risk factors for narrow-angle glaucoma must also not use this medicine.

Age- and Condition-Based Restrictions

Age-related restrictions apply to children younger than 13 years, for whom monotherapy safety and efficacy are not established. Use is allowed for adults and adolescents 13 years and older for labeled indications. For pregnant patients, use is restricted to cases where the potential benefit justifies the risk; neonates require monitoring for withdrawal symptoms. Use while breastfeeding is not recommended.

Conditional use applies to populations requiring caution and monitoring, including patients with hepatic impairment, renal impairment, a history of seizures, or pre-existing conditions like diabetes mellitus and cardiovascular disease.

What should I know about interactions with other medicines?

Olaxinn Interactions with Other Medicines and Products

This section outlines the officially documented interaction patterns for Olaxinn (Olanzapine), based strictly on government regulatory sources.

Documented Metabolic Interactions

Olaxinn is primarily cleared by the liver enzyme CYP1A2. Interactions that affect this enzyme are officially noted to alter Olaxinn’s plasma levels.

Interaction Type Interacting Substance Resulting Effect on Olaxinn Exposure
Inhibition (Decreased Clearance) Fluvoxamine, Ciprofloxacin Significantly increases Olaxinn plasma levels
Induction (Increased Clearance) Carbamazepine, Smoking Significantly decreases Olaxinn plasma levels

Pharmacodynamic and Additive Effects

Caution is advised with co-administration of substances that share effects with Olaxinn, potentially leading to additive risks.

  • Centrally Acting Drugs and Alcohol: Officially noted for the potential to cause additive CNS effects, such as increased sedation.
  • Antihypertensive Agents: May result in an enhanced hypotensive effect.
  • QTc-Prolonging Medicines: Co-administration requires caution due to potential additive QTc interval increase.
  • Levodopa and Dopamine Agonists: Olaxinn may antagonize the effects of these agents.

Physical Absorption and Population Notes

Activated Charcoal is documented to significantly reduce the oral bioavailability of Olaxinn. Regulatory documents also note that factors associated with slower metabolism, such as female gender, geriatric age, and non-smoking status, should be considered as they may intensify the effect of metabolic inhibitors.

Mechanism of Action

The mechanism of Olaxinn (Olanzapine) is defined by its polypharmacological profile, characterized by simultaneous antagonism at multiple central nervous system (CNS) receptors. This action initiates the modulation of signaling pathways that influence complex neural processes.

Dual-System Modulation via D2 and 5-HT2A Antagonism

Olanzapine's primary molecular interaction is the blocking of Dopamine D2 and Serotonin 5-HT2A receptors. This interaction kinetically alters activity within neural pathways responsible for sensory pathway modulation, influencing the net output of affected CNS systems. The drug's easily dissociable binding at the D2 receptor influences the pattern of dopaminergic signal transduction.

Interaction with Arousal and Peripheral Physiological Systems

The molecule also acts as an antagonist on secondary targets, notably Histamine H1 and Adrenergic alpha1 receptors. H1 receptor blockade suppresses the histaminergic arousal system, resulting in altered CNS signaling related to wakefulness. Concurrently, alpha1 antagonism causes adjustments in peripheral vascular tone and blood pressure regulation.

Mechanism Constraints Due to Non-Selectivity

The molecule's broad binding profile, including sites integral to central energy homeostasis, can intrinsically influence physiological set points by affecting pathways related to metabolic regulation.

Dosage and Administration Information

How to Use Olaxinn

Olaxinn (olanzapine) is administered according to guidelines that define the approved routes, standardized dosing, and administration schedules. These instructions are derived from official prescribing documentation.


Approved Administration Methods

Route/Form Use Context Key Instruction
Oral Tablet/ODT Long-term maintenance Taken once daily, with or without food.
IM Injection (Immediate-Release) Acute symptom stabilization Given up to 3 times in 24 hours; not to exceed 30 mg total.
IM Injection (Long-Acting) Maintenance (extended-release) Administered by deep gluteal injection every 2 or 4 weeks.

Standardized Dosing and Schedules

The recommended oral starting dose for adults with Schizophrenia is typically 10 mg once daily. The usual maintenance range is 5 mg to 20 mg/day, and the maximum recommended daily oral dose is 20 mg. For acute agitation, the immediate-release intramuscular dose is typically 10 mg.

Administration Adjustments and Procedural Rules

Dose Titration: Changes to the oral dose should generally occur at intervals of not less than 24 hours to one week, depending on the indication, and should be made in 5 mg increments or decrements.

Special Populations: A lower oral starting dose of 5 mg/day should be considered for older adults (65 years and older) and patients with hepatic or renal impairment. For adolescents (13-17 years), the recommended starting dose is 2.5 mg to 5 mg, with a maximum of 20 mg/day.

Injection Preparation: The immediate-release powder for injection must be reconstituted only with sterile water for injection and used immediately. Administration of the long-acting injection requires a minimum 2-hour observation period after each dose.

Recent Clinical Evidence

Olaxinn: Recent Clinical Evidence

This section describes the research that has been conducted on Olaxinn, focusing only on the types of studies, the populations examined, and what has been observed so far. It does not offer personal medical advice or make claims about how the medication will work for any individual.

Evidence for use in Schizophrenia (Adults and Adolescents)

Research for schizophrenia includes numerous short-term randomized controlled trials (RCTs). These studies were used in research exploring how symptoms change over time in patients experiencing a period of increased symptom activity. Long-term research, referred to as maintenance trials, monitors measures of symptom stabilization over extended time intervals. Findings describe patterns observed in studies related to symptom scores, and trials consistently monitored metabolic and physiological strain outcomes, such as changes in weight and blood markers.

Evidence for use in Bipolar I Disorder (Manic or Mixed Episodes)

Olaxinn was evaluated in research exploring manic or mixed phases of Bipolar I Disorder. Research examined its use as a single treatment (monotherapy) and as an adjunctive treatment. These trials primarily focused on outcomes capturing phases of heightened symptom activity, using validated scales to examine outcomes. The evidence contributes to the broader evidence landscape related to short-term changes in symptoms.

What Is Still Uncertain About Olaxinn Research

Research provides context but not individual predictions, and findings describe group patterns, not personal outcomes. Long-term effects, particularly regarding the observation of metabolic changes, are not fully established beyond the duration of the clinical trials. This is a topic where research is ongoing. Comparative evidence is limited for very low doses, and data show varying patterns in real-world studies exploring lower dosing patterns. Subgroup findings remain uncertain due to the modest sample sizes in some trials. Evidence for certain groups, such as older adults and those with co-occurring illnesses, is generally less comprehensive compared to the general adult population.

Key Studies & References

  1. Psychosis and schizophrenia in adults: prevention and management - NICE Guideline CG178

Frequently Asked Questions (FAQ)

Common questions about Olaxinn (FAQ)


Q: Why is Olaxinn not available over the counter?

Olaxinn is classified as a prescription-only medication. This is because it is used to help stabilize serious conditions and requires ongoing medical supervision and monitoring. While it is not a controlled substance, official information emphasizes the need for regular health checks due to potential serious side effects, supporting its appropriate use.


Q: Can Olaxinn be crushed or split if the pill is too large?

Official product information advises that the Orally Disintegrating Tablet (ODT) form should not be cut, crushed, or chewed and should be disposed of if it breaks apart. For the standard oral tablet, specific instructions are usually to swallow the tablet whole. Official guidance generally suggests avoiding alteration of the tablet form unless specifically instructed by a healthcare professional, as this could affect how the medicine performs.


Q: Can Olaxinn interact with common over-the-counter cold medicines?

Official documents caution against combining Olaxinn with other centrally acting drugs, which includes many common over-the-counter cold and flu medicines. These combinations can potentially lead to additive effects on the Central Nervous System (CNS), such as significantly increased drowsiness or sedation. Official guidance emphasizes that patients should review all other medications, including OTC products, with their healthcare provider.


Q: What is the expected timeline for seeing the full 'benefit' of Olaxinn?

Based on clinical study observations, the therapeutic effects of Olaxinn are generally seen gradually over time. While the drug reaches its highest concentration in the blood within hours, the onset of the full anticipated effects is typically observed after one to two weeks of consistent treatment. Continued stabilization is often observed over extended periods of maintenance treatment.


Q: How quickly does Olaxinn start working?

The drug begins to enter the body's system quickly. After taking an oral dose, official pharmacological data indicates that Olaxinn reaches its highest concentration in the bloodstream, known as peak plasma levels, within about five to eight hours. This initial absorption is part of the overall process leading to the drug’s effects.


Q: How long does the effect of Olaxinn last?

Official product information defines the duration of the drug's presence in the body by its half-life, which is the time it takes for half of the dose to be eliminated. The average elimination half-life of Olaxinn is approximately 30 hours, though it can range wider. This relatively long duration supports its standard dosing schedule of being taken once daily.


Q: Are there any common foods that should be avoided when taking Olaxinn?

According to official regulatory information, Olaxinn can be taken with or without food, as food does not impact how the medication is absorbed by the body. Official guidance indicates that alcohol should not be consumed, as it can increase the drug's effects on the Central Nervous System, leading to enhanced sedation.


Q: Does Olaxinn have any known interactions with herbal supplements?

Regulatory patient information advises caution regarding the use of herbal remedies and dietary supplements. This warning primarily applies to supplements that themselves cause sleepiness or dizziness, as taking them with Olaxinn may increase those side effects. Official information suggests informing a medical provider about all herbal products being used.


Q: Does Olaxinn have a risk of dependence or addiction?

Olaxinn is not classified as a controlled substance by major regulatory bodies. Official patient information generally indicates that the drug is not associated with risk of addiction or dependence. However, abruptly stopping the medicine can lead to withdrawal symptoms. Regulatory safety information indicates that discontinuation should occur only under medical guidance.


Q: Is there a generic version of Olaxinn available?

Yes, the active ingredient in Olaxinn, olanzapine, is available in a generic formulation. This generic version is recognized by regulatory authorities as a lower-cost alternative to the branded product.


Q: What should I do if I miss a dose of Olaxinn?

Official patient information describes the general procedure for a missed dose, which typically involves taking the dose when remembered unless it is near the next scheduled time. The information explicitly notes that regulatory guidance is to never take a double dose to compensate for a missed dose. Specific directions on timing should be obtained directly from the prescribing healthcare provider.


Q: Will Olaxinn interact with birth control pills?

Regulatory information suggests that when taken together, Olaxinn and medicines containing ethinyl estradiol (a component found in many birth control pills) may potentially increase the concentration of Olaxinn in the bloodstream. This could lead to a higher risk of certain side effects, like increased drowsiness or dizziness.


Q: Is Olaxinn considered a controlled substance?

No, Olaxinn is not considered a controlled substance by the US Drug Enforcement Administration (DEA). This means it is not legally classified among drugs that carry a high potential for abuse or dependence.


Q: Can Olaxinn affect my ability to drive or operate machinery?

Regulatory documents specifically warn that Olaxinn has the potential to impair a patient's judgment, thinking, and motor skills. Regulatory documents note that caution is generally recommended regarding driving, operating complex machinery, or participating in hazardous activities until the effects of the medication on the individual are known.


Q: Does Olaxinn come in different strengths?

Yes, the oral tablet form of Olaxinn is available in a range of different strengths to accommodate different treatment needs as determined by a healthcare provider. Official product documentation lists multiple options, typically including 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg doses.


Q: Is Olaxinn a new drug, or has it been around for a while?

The core medicine, olanzapine, has been available for a significant period. It was originally approved by the FDA in the mid-1990s. Since then, various formulations of the drug, such as the orally disintegrating tablet (ODT) and the long-acting injection, have received later regulatory approvals.


How should Olaxinn be stored and disposed of?

How to Store and Dispose of Olaxinn?

Olaxinn (olanzapine) must be stored at controlled room temperature, typically defined as 20 C to 25 C (68 F to 77 F). The medication must be kept in its original container, which should be tightly closed, and actively protected from light and moisture. Storage rules mandate that all forms of Olaxinn must be kept out of the sight and reach of children to prevent accidental ingestion.


Disposal Requirements

Specific disposal instructions apply to the different forms. Unused or expired Orally Disintegrating Tablets (ODT) should be removed from the packaging, mixed with water, and discarded into a toilet. For other formulations, if no drug take-back program is available, the product must be mixed with an undesirable substance, placed in a sealed bag, and disposed of in the household trash, following general FDA guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Olaxinn found in:

A-Z Index: